Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas-Reference-Cited by-同舟云学术

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas

Published:2021-09-20 Issue:2 Volume:36 Page:588-590
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Marchesi Francesco^ORCID,Pimpinelli Fulvia,Giannarelli Diana,Ronchetti Livia,Papa Elena,Falcucci Paolo,Pontone Martina,Di Domenico Enea Gino,di Martino Simona,Laquintana Valentina,Mandoj Chiara,Conti Laura,Cordone Iole,La Malfa Antonia,Viggiani Caterina,Renzi Daniela,Palombi Francesca,Romano Atelda,Pisani Francesco,Gumenyuk Svitlana,Di Bella Ornella,Vujovic Branka,Morrone Aldo,Ciliberto Gennaro,Ensoli Fabrizio,Mengarelli Andrea

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01418-8.pdf

Reference10 articles.

1. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73. https://doi.org/10.1182/blood.2021011568.

2. Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021 May 13:1–3. https://doi.org/10.1038/s41375-021-01270-w.

3. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week-immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single Institution. J Hematol Oncol. 2021;14:81. https://doi.org/10.1186/s13045-021-01090-6.

4. Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5:3053–61. https://doi.org/10.1182/bloodadvances.2021005094.

5. Gurion R, Rozovski U, Itchaki G, Gafter-Gvili A, Leibovitch C, Raanani P, et al. Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies. Haematologica. 2021 Jul 29. https://doi.org/10.3324/haematol.2021.279216.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects;Frontiers in Immunology;2024-01-26

2. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies;Cureus;2024-01-10

3. The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic;Frontiers in Medicine;2023-09-07

4. Multicenter cohort study of the risk factors and mortality of Omicron variant SARS-CoV-2-infected patients with hematologic malignancies in hospitals;2023-06-26

5. Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies;Life;2023-05-28